从鼠到人:骨关节炎共同分子机制的探索
本文综述了骨关节炎靶点发现的困境与进展,指出过去关于骨关节炎是衰老必然结果、软骨不能自我修复、以及由类似类风湿关节炎的滑膜炎症驱动的误解已被分子研究重塑。从类风湿关节炎重用的治疗在随机对照试验中大多失败,而全基因组研究提示修复通路缺陷,生长因子疗法或Wnt通路拮抗带来希望,神经生长因子在2-3期试验中成为骨关节炎疼痛的稳健靶点。
要点
- 骨关节炎炎症与类风湿关节炎不同,从类风湿关节炎重用的治疗在随机对照试验中大多失败。
- 全基因组研究提示修复通路缺陷,与生长因子疗法或Wnt通路拮抗的近期希望一致。
- 神经生长因子在2-3期试验中成为骨关节炎疼痛的稳健靶点。
核心结论
- 骨关节炎的分子认识已发生根本性转变,从小鼠临床前模型识别的致病机制可引导出有效的人类靶点。
研究设计与样本
- 本文为综述,通过离体组织分析、体外研究和临床前模型对骨关节炎进行分子 interrogations,并汇总近期随机对照试验和全基因组研究。
主要发现
- 骨关节炎中的炎症似乎与类风湿关节炎中所见不同。
- 使用从类风湿关节炎重用的治疗的近期随机对照试验大多不成功。
- 全基因组研究指向修复通路缺陷,与生长因子疗法或Wnt通路拮抗的近期前景相吻合。
- 神经生长因子在2-3期试验中已成为骨关节炎疼痛的稳健靶点。
临床怎么用
- 应认识到骨关节炎并非衰老的必然结果,也非类风湿关节炎样滑膜炎症驱动,避免简单重用类风湿关节炎治疗。
- 关注修复通路缺陷相关靶点,如生长因子疗法或Wnt通路拮抗,以及神经生长因子用于疼痛管理的前景。
局限性
- 原文未报告具体研究样本量、效应量或统计阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite an increasing burden of osteoarthritis in developed societies, target discovery has been slow and there are currently no approved disease-modifying osteoarthritis drugs. This lack of progress is due in part to a series of misconceptions over the years: that osteoarthritis is an inevitable consequence of ageing, that damaged articular cartilage cannot heal itself, and that osteoarthritis is driven by synovial inflammation similar to that seen in rheumatoid arthritis. Molecular interrogation of disease through ex-vivo tissue analysis, in-vitro studies, and preclinical models have radically reshaped the knowledge landscape. Inflammation in osteoarthritis appears to be distinct from that seen in rheumatoid arthritis. Recent randomised controlled trials, using treatments repurposed from rheumatoid arthritis, have largely been unsuccessful. Genome-wide studies point to defects in repair pathways, which accords well with recent promise using growth factor therapies or Wnt pathway antagonism. Nerve growth factor has emerged as a robust target in osteoarthritis pain in phase 2-3 trials. These studies, both positive and negative, align well with those in preclinical surgical models of osteoarthritis, indicating that pathogenic mechanisms identified in mice can lead researchers to valid human targets. Several novel candidate pathways are emerging from preclinical studies that offer hope of future translational impact. Enhancing trust between industry, basic, and clinical scientists will optimise our collective chance of success.
引用
- Vincent TL. Of mice and men: converging on a common molecular understanding of osteoarthritis. Lancet Rheumatol. 2020. PMID: 32989436. doi:10.1016/S2665-9913(20)30279-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。